Latest News in Gastric Cancer From ASCO GI

Dr. Geoffrey Y. Ku explores key updates from the ASCO GI Cancers Symposium, including a bispecific antibody in HER2-positive tumors, as well as the approval of trastuzumab deruxtecan.

ASCO GI 2021: HER2-Positive Gastric Cancer, POLO and Key Trials in Progress

Dr. Lola A. Fashoyin-Aje outlines her top picks from 2021 ASCO GI Cancers Symposium including a talk evaluating key recent milestones in the treatment of HER2-positive gastric cancers...

DESTINY-Gastric03: Trastuzumab Deruxtecan in HER2-Overexpressing Gastric Cancer

Dr. Yelena Y. Janjigian discusses the ongoing DESTINY-Gastric03 study, a Phase Ib/II, dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan monotherapy and...


ATTRACTION-4: Nivolumab Plus Chemotherapy for Gastric or Gastroesophageal Cancer

Prof. Narikazu Boku speaks to ecancer in an online interview for the virtual ESMO 2020 meeting about the ATTRACTION-4 study results.

Personalizing Gastric Cancer Care With HER2-Targeted and Other Novel Therapies

Dr. David H.

GASTHER2: Trastuzumab for Advanced Gastric Cancer

Dr. Rachel Riechelmann outlines the rationale behind the GASTHER2 study evaluating trastuzumab for patients with advanced gastric cancer with HER2+ expression in circulating tumour cells.

Gemtesa, Enhertu, & Cabenuva

This episode highlights the new indication for Enhertu regarding HER2+ GI cancer.

Josep Tabernero, MD, PhD - Optimizing Precision Medicine in Gastric Cancer Care

Dr Josep Tabernero gives his perspective on the latest evidence on novel HER2-targeted and other molecular-directed therapies in gastric cancer.

Optimizing Precision Medicine in Gastric Cancer Care: Essential Guidance on Translating Scientific Advances With Novel HER2-Targeted Therapies and Other Agents Into Current Clinical Practice

These experts examine best practices for testing biomarkers such as HER2, PD-L1, and MSI, and provide guidance on integrating scientific advances and novel therapeutics into...

Up Close and Personalizing Gastric Cancer Care: Precision Medicine With HER2-Targeted Therapies and Other Novel Agents

An expert panel provides the latest efficacy and safety data for established and emerging therapeutics for gastric cancer including HER2-directed antibody–drug conjugates and addresses...

Increasing Importance of HER2 and HER3 Testing in the Context of an Expanding Targeted Therapies Landscape for Breast, Gastrointestinal, Lung, and Other Cancers

Review evidence-based guidelines and expert recommendations regarding HER2 testing and interpretation of results in breast, gastric, colorectal, non–small cell lung, and other cancers.

Dr. Andres Cervantes Discusses Trastuzamab Deruxtecan as Emerging Therapy for Gastric Cancer

Dr Cervantes highlights the significance of the DESTINY-Gastric01 trial and new advancements in treatment of HER2+ gastric cancer.


Findings From the 2021 Gastrointestinal Cancers Symposium

This podcast covers the findings with three study authors from the virtual 2021 ASCO GI Cancers Symposium.

ESMO-Magnitude of Clinical Benefit Scale of Adjuvant Colon Cancer Trials and Meta-Analyses

Form 1 of the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale serves to grade therapies with curative intent.

Gastric/GE Junction Cancer – Geoffrey Ku, MD, and Robert Figlin, MD

 Geoffrey Ku, MD, and Robert Figlin, MD, discuss recent clinical developments in gastric and esophageal cancer.

ASCO 2020: New Developments in the Treatment of Hard to Treat Cancers

Drs Hofland and Massacesi discuss the company’s partnerships with Daiichi Sankyo in developing a very targeted drug  for the treatment of patients with HER2+ advanced gastric cancer.

ESMO Open - ASCO - Practice Changing Studies in Gastrointestinal Cancer

In this podcast new, practice-changing research in GI cancer is considered.

Dr. S. Lindsey Davis Highlights Key Abstracts on GI Cancers from the #ASCO20 Virtual Scientific Program

Dr. S. Lindsey Davis, medical oncologist and assistant professor at the University of Colorado Cancer Center, highlights key abstracts on GI cancers that were featured at ASCO20.

Oncology Today With Dr Neil Love: Gastrointestinal Cancers Edition

A discussion of various treatments and therapies for gastric cancer, including HER2+ advanced gastric/GEJ cancer.

Response Rate in Phase I trials, JACOB, and MI, Stroke, and Metastasis as Hard Endpoints

This podcast discusses the JACOB trial published on pertuzumab for HER2-positive gastric cancer.

Gastric Cancer Deep Dive

This podcast briefly reviews the historical gastric cancer classifications and explains how this has drastically changed over the past 5-10 years with the advent of next-generation...

Colon and Rectal Cancer – David Ilson, MD, and Robert Figlin, MD

Drs David Ilson and Robert Figlin discuss recent clinical advances in colon and rectal cancer from ASCO20 Virtual.


source list reference